An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Volasertib (Primary) ; Itraconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 21 Sep 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2017.
- 21 Sep 2017 Status changed from completed to active, no longer recruiting.
- 13 Sep 2017 Status changed from active, no longer recruiting to completed.